ANI Pharmaceuticals (NasdaqGM:ANIP) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold ANI Pharmaceuticals to reach your target.
Based on historical returns, we believe that ANI Pharmaceuticals can grow its free cash at a rate of about 1%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| ANIP Price (ANI Pharmaceuticals stock price per share) |
$69.13 | |
|
|
ANIP Fair Price (based on intrinsic value) |
$23.80 |
| ANIP Safety Price (based on a variable margin of safety) | $14.28 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 29% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 55% higher than other Drug Manufacturers - General stocks | |
| Free Cash Flow Jitter | 173% | |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 3,583,674 shares shorted. With 19,423,900 shares available for purchase and an average trading volume over the past 10 trading days of 663,140, it would take at least 5.4 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2009 | 1023024 | -18.6 |
| 2010 | 1023024 | -40.2 |
| 2011 | 1023024 | -48.2 |
| 2012 | 1023024 | -0.4 |
| 2013 | 1023024 | -5.8 |
| 2014 | 1023024 | 21.6 |
| 2015 | 1023024 | 16.4 |
| 2016 | 1023024 | 25.8 |
| 2017 | 1023024 | 35.7 |
| 2018 | 1023024 | 62.3 |
| 2019 | 1023024 | 39.7 |
| 2020 | 1023024 | 8.6 |
| 2021 | 1023024 | -3 |
| 2022 | 1023024 | -37.2 |
| 2023 | 1023024 | 112 |
| 2024 | 1023024 | 55.5 |
| 2025 | 1023024 | 175 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 8 fiscal years from 2012 to 2025 with positive net income, operating cash flow totaled $478 million against net income of $167 million, or 2.86 times. Net income was negative in 6 of the 14 years, and those years are left out of the ratio.
In 2025, operating cash flow was 2.36 times net income, compared with 0.57 times for the earliest three years (2012 to 2014).
In 2025, capital expenditures were $13.8 million, 7.5% of operating cash flow of $185 million, which leaves an estimated $171 million after capex. Across the 11 years with reported capex, it averaged 12.9% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2012 | -1.5 | -0.1 | 0.3 | n/a |
| 2013 | 0.3 | -5.5 | 0.2 | -18.22 |
| 2014 | 28.7 | 22 | 1.1 | 0.77 |
| 2015 | 15.4 | 17.3 | 2.2 | 1.12 |
| 2016 | 3.9 | 27.5 | 4.6 | 6.98 |
| 2017 | -1.1 | 39.4 | 10.4 | n/a |
| 2018 | 15.5 | 67.1 | 5.7 | 4.33 |
| 2019 | 6.1 | 45.6 | 6.6 | 7.49 |
| 2020 | -22.5 | 15.3 | 6.1 | n/a |
| 2021 | -42.6 | 3.3 | 2.6 | n/a |
| 2022 | -47.9 | -31.2 | 8.9 | n/a |
| 2023 | 18.8 | 119 | 8.9 | 6.33 |
| 2024 | -18.5 | 64 | 16.2 | n/a |
| 2025 | 78.3 | 185 | 13.8 | 2.36 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 9 fiscal years from 2013 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $371 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In the 5 of those years with dividend payment facts, dividends paid totaled $6.2 million, 2.1% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 3 of those 5 years.
In 4 of the 9 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $27.2 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2025, dividends and cash spent repurchasing shares together were $13.4 million, 7.6% of estimated free cash flow of $175 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2013 | -5.8 | n/a | 0.4 | 0.4 | n/a |
| 2016 | 25.8 | n/a | 2.5 | 2.5 | 9.7% |
| 2019 | 39.7 | n/a | 1 | 1 | 2.6% |
| 2020 | 8.6 | n/a | 1.5 | 1.5 | 17.8% |
| 2021 | -3 | 0.2 | 0.9 | 1.1 | n/a |
| 2022 | -37.2 | 1.6 | 2 | 3.6 | n/a |
| 2023 | 112 | 1.6 | 5 | 6.6 | 5.9% |
| 2024 | 55.5 | 1.6 | 11 | 12.6 | 22.7% |
| 2025 | 175 | 1.2 | 12.2 | 13.4 | 7.6% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $1.3 million in 2009 and $883 million in 2025, a compound annual growth rate of 50.6% over 16 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.
Revenue rose 43.8% from 2024 to 2025.
Our estimated free cash flow was $175 million in 2025, 19.8% of revenue. In 2009 the estimated margin was negative 1478.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 1.3 | -18.6 | -1478.2% |
| 2010 | 2.5 | -40.2 | -1625.2% |
| 2011 | 0.4 | -48.2 | -11073.3% |
| 2012 | 20.4 | -0.4 | -2.2% |
| 2013 | 30.1 | -5.8 | -19.2% |
| 2014 | 56 | 21.6 | 38.5% |
| 2015 | 76.3 | 16.4 | 21.4% |
| 2016 | 129 | 25.8 | 20.1% |
| 2017 | 177 | 35.7 | 20.2% |
| 2018 | 202 | 62.3 | 30.9% |
| 2019 | 207 | 39.7 | 19.2% |
| 2020 | 208 | 8.6 | 4.1% |
| 2021 | 216 | -3 | -1.4% |
| 2022 | 316 | -37.2 | -11.8% |
| 2023 | 487 | 112 | 23.1% |
| 2024 | 614 | 55.5 | 9.0% |
| 2025 | 883 | 175 | 19.8% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $286 million against total liabilities of $900 million, or 31.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 62.5% of total assets in 2025, compared with 57.2% in 2010, an increase of 5.2 percentage points.
Stockholders equity was $541 million in 2025, compared with $19.1 million in 2010, a rise of 2724.0%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 20.0% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 44.8 | 38.2 | 25.6 | 19.1 |
| 2011 | 62.4 | n/a | 96.7 | -34.3 |
| 2012 | 13.7 | 0 | 56.5 | -42.7 |
| 2013 | 44.5 | 11.1 | 3.5 | 41 |
| 2014 | 260 | 169 | 120 | 140 |
| 2015 | 285 | 155 | 125 | 160 |
| 2016 | 323 | 27.4 | 153 | 170 |
| 2017 | 412 | 31.1 | 237 | 175 |
| 2018 | 431 | 43 | 233 | 197 |
| 2019 | 457 | 62.3 | 244 | 213 |
| 2020 | 461 | 7.9 | 265 | 196 |
| 2021 | 772 | 100 | 438 | 334 |
| 2022 | 760 | 48.2 | 446 | 314 |
| 2023 | 904 | 221 | 472 | 433 |
| 2024 | 1,284 | 145 | 881 | 404 |
| 2025 | 1,440 | 286 | 900 | 541 |
Positive free cash flow appears in 10 of the 17 fiscal years we hold for ANI Pharmaceuticals from its current SEC filer.
Free cash flow is volatile from year to year, with a variability measure of 173%.
At $69.13, ANI Pharmaceuticals trades above our fair value estimate of $23.80.
No dividend yield is recorded for ANI Pharmaceuticals in our data.
These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 29% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 55% above the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to ANI Pharmaceuticals, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| ANI Pharmaceuticals (ANIP) | 1,571 | 14.0 | - | - | 190% above |
| Phibro Animal Health Corporation (PAHC) | 1,384 | 13.6 | 1.3% | - | 87% above |
| Innoviva (INVA) | 1,309 | 7.8 | - | - | 12% above |
| Amphastar Pharmaceuticals (AMPH) | 1,199 | 12.9 | - | 0.8% | 97% above |
| Perrigo Company plc (PRGO) | 2,226 | - | 6.8% | 68.6% | 91% below |
| Prestige Consumer Healthcare (PBH) | 2,351 | 15.3 | - | 7.6% | 50% below |
| Collegium Pharmaceutical (COLL) | 783 | 23.1 | - | - | 160% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1023024.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: ANIP annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does ANI Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to ANIP: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is Dollar Cost Averaging?
Benjamin Graham, Value Investor
How Do Tariffs Affect the Stock Market?
Precious Metals for Value Investors